Abstract: The present invention relates to compositions and methods of treating a cognitive disorder in a subject by administering an effective amount of phenserine or a pharmaceutically acceptable salt thereof and an effective amount of memantine or a pharmaceutically acceptable salt thereof to a subject, thereby treating a cognitive disorder in the subject.

Abstract: Phenserine compounds and pharmaceutically acceptable salts thereof are found to be useful in the management or treatment of diabetes and/or complications, such as vascular dementia, and insulin resistance, associated with diabetes. The phenserine compounds of the invention are carbamates that inhibit the activity of acetylcholinesterase.

Abstract: Described is the efficient synthesis of an easy to manipulate and utilize, soluble tartrate salt of a potent, reversible butyrylcholinesterase inhibitor, (?)-(3aS)-3a-methyl-1,2,3,3a,8,8a-hexahydropyrrolo-[2,3-b]indol-5-yl N—4?-isopropylphenylcarbamate (“MHI tartrate”), for use in altering the enzymatic activity of butyrylcholinesterase and/or acetylcholinesterase in a subject exhibiting or predicted to exhibit cognitive disorders associated with diabetes. Subjects may be suffering from or predicted to suffer from abnormal acetylcholinesterase and/or butyrylcholinesterase activity levels or from an inability to metabolize or catabolize blood sugar normally. The method comprises administering to the subject an effective amount of MHI tartrate dispensable in discrete pharmaceutically useful dosages. MHI tartrate effectively inhibits both acetylcholinesterase and butyrylcholinesterases and additionally is highly selective for butyrylcholinesterase over acetylcholinesterase.

Abstract: The present invention relates to compositions and methods of treating a cognitive disorder in a subject by administering an effective amount of a phenserine compound or a pharmaceutically acceptable salt or ester thereof and an effective amount of a HMG CoA reductase inhibitor or a pharmaceutically acceptable salt thereof to a subject, thereby treating a cognitive disorder in the subject.

Abstract: An improved transdermal delivery composition is provided containing a low molecular weight fatty acid, and a long chain fatty acid or a long chain fatty acid lower alkyl ester, wherein the long chain is between about 1 to about 21 carbons long and preferably, contains at least one cis-olefinic bond. Preferred long chain components are oleic acid and ethyl oleate while the preferred low molecular weight fatty acid is propionic acid. The product may be used for treating a cognitive disorder by administering phenserine through a subject's skin.

Abstract: The present invention relates to an improved method of treating, reducing or delaying cognitive impairments associated with the ?-amyloid peptide, either in combination with treatment by cholinomimetic replacement therapy or as a prophylactic treatment.

Abstract: Compositions and methods for the treatment of diseases resulting from cognitive Disorders, such as Alzheimer's diseases with the compound (−) N-(−)-N phenyl canbamoyleseroline as the active ingredient.